Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Eric Wu

TitleAffiliate - DHHA
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-EM MED Clinical

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gong B, Cheng LJ, Young CH, Krishnan P, Wang Y, Wei H, Zhou C, Wei S, Li Y, Fang Q, Zhong J, Wu EQ, Mi Y, Wang J. Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study. Ther Clin Risk Manag. 2024; 20:59-73. PMID: 38347921.
      View in: PubMed
    2. Liu Y, Skup M, Yang M, Qi CZ, Wu EQ. Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. Adv Ther. 2022 Nov; 39(11):5300. PMID: 36040636.
      View in: PubMed
    3. Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. J Health Econ Outcomes Res. 2022; 9(2):19-29. PMID: 35979528.
      View in: PubMed
    4. Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm. 2022 Jul; 28(7):740-752. PMID: 35737858.
      View in: PubMed
    5. Liu Y, Skup M, Yang M, Qi CZ, Wu EQ. Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. Adv Ther. 2022 08; 39(8):3711-3734. PMID: 35737227.
      View in: PubMed
    6. Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States. Adv Ther. 2022 08; 39(8):3547-3559. PMID: 35689161.
      View in: PubMed
    7. Lin F, Kwong WJ, Shi S, Pivneva I, Wu EQ, Abraham JA. Erratum: Author Correction: Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United States. J Health Econ Outcomes Res. 2022; 9(1):33289. PMID: 35937976.
      View in: PubMed
    8. Lin F, Kwong WJ, Shi S, Pivneva I, Wu EQ, Abraham JA. Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United States. J Health Econ Outcomes Res. 2022; 9(1):68-74. PMID: 35620453.
      View in: PubMed
    9. Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ. Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis. Adv Ther. 2022 02; 39(2):1033-1044. PMID: 34958445.
      View in: PubMed
    10. Xie J, Wu EQ, Wang S, Cheng T, Zhou Z, Zhong J, Liu L. Real-World Data for Healthcare Research in China: Call for Actions. Value Health Reg Issues. 2022 Jan-Feb; 27:72-81. PMID: 34844062.
      View in: PubMed
    11. Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value Health. 2021 11; 24(11):1628-1633. PMID: 34711363.
      View in: PubMed
    12. Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ. Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. Adv Ther. 2021 10; 38(10):5238-5252. PMID: 34471991.
      View in: PubMed
    13. Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D. Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers. Neurol Ther. 2021 Jun; 10(1):293-306. PMID: 33856626.
      View in: PubMed
    14. Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv. 2021 04 13; 5(7):1954-1962. PMID: 33830206.
      View in: PubMed
    15. Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu EQ, Kwong WJ, Abraham JA. The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States. J Occup Environ Med. 2021 04 01; 63(4):e197-e202. PMID: 33560066.
      View in: PubMed
    16. Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. Transplant Cell Ther. 2021 06; 27(6):506.e1-506.e10. PMID: 33823168.
      View in: PubMed
    17. Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Leuk Lymphoma. 2021 06; 62(6):1411-1421. PMID: 33430673.
      View in: PubMed
    18. Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. J Med Econ. 2021 Jan-Dec; 24(1):234-243. PMID: 33472483.
      View in: PubMed
    19. Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. Transplant Cell Ther. 2021 03; 27(3):241.e1-241.e11. PMID: 33781519.
      View in: PubMed
    20. Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020 08; 36(8):1333-1341. PMID: 32459116.
      View in: PubMed
    21. Yang H, Hao Y, Qi CZ, Chai X, Wu EQ. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective. J Manag Care Spec Pharm. 2020 Aug; 26(8):971-980. PMID: 32525730.
      View in: PubMed
    22. Yang H, Hao Y, Chai X, Qi CZ, Wu EQ. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective. J Med Econ. 2020 Sep; 23(9):1016-1024. PMID: 32397772.
      View in: PubMed
    23. Liu G, Wu EQ, Ahn J, Kamae I, Xie J, Yang H. The Development of Health Technology Assessment in Asia: Current Status and Future Trends. Value Health Reg Issues. 2020 May; 21:39-44. PMID: 31634795.
      View in: PubMed
    24. Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ. The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis. J Manag Care Spec Pharm. 2019 Dec; 25(12):1398-1408. PMID: 31566054.
      View in: PubMed
    25. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. Adv Ther. 2019 11; 36(11):2982-2985. PMID: 31512141.
      View in: PubMed
    26. Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections. Adv Ther. 2019 09; 36(9):2475-2486. PMID: 31240629.
      View in: PubMed
    27. Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review. Adv Ther. 2019 08; 36(8):1851-1877. PMID: 31168766.
      View in: PubMed
    28. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Adv Ther. 2019 05; 36(5):1164-1176. PMID: 30879249.
      View in: PubMed
    29. Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. Eur Urol Oncol. 2019 02; 2(1):12-20. PMID: 30929841.
      View in: PubMed
    30. Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA. Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer. Adv Ther. 2018 Aug; 35(8):1251-1264. PMID: 29946797.
      View in: PubMed
    31. Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018 07; 34(7):1325-1333. PMID: 29619856.
      View in: PubMed
    32. Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R. Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis. Diabetes Ther. 2018 Jun; 9(3):1021-1036. PMID: 29600504.
      View in: PubMed
    33. Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. Adv Ther. 2018 04; 35(4):482-493. PMID: 29582246.
      View in: PubMed
    34. Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018 06; 34(6):971-978. PMID: 29368958.
      View in: PubMed
    35. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The Cost of Hyperkalemia in the United States. Kidney Int Rep. 2018 Mar; 3(2):385-393. PMID: 29725642.
      View in: PubMed
    36. Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2017 Sep; 26(9):1996-2003. PMID: 28689999.
      View in: PubMed
    37. Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. J Manag Care Spec Pharm. 2017 Jul; 23(7):771-780. PMID: 28650249.
      View in: PubMed
    38. Soliman AM, Du EX, Yang H, Wu EQ, Haley JC. Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy. J Womens Health (Larchmt). 2017 06; 26(6):644-654. PMID: 28472602.
      View in: PubMed
    39. Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ. A Risk Score for Fluconazole Failure among Patients with Candidemia. Antimicrob Agents Chemother. 2017 05; 61(5). PMID: 28264843.
      View in: PubMed
    40. Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ. Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests. J Med Econ. 2017 Aug; 20(8):777-785. PMID: 28406042.
      View in: PubMed
    41. Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R. Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther. 2017 Jun; 8(3):555-571. PMID: 28361464.
      View in: PubMed
    42. Bollu V, Guérin A, Gauthier G, Hiscock R, Wu EQ. Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized ß2-Agonists. Drugs Real World Outcomes. 2017 Mar; 4(1):33-41. PMID: 27864792.
      View in: PubMed
    43. Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Adv Ther. 2017 01; 34(1):207-220. PMID: 27913989.
      View in: PubMed
    44. Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017 Feb; 20(2):121-128. PMID: 27570999.
      View in: PubMed
    45. Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A. Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-a and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis. Rheumatol Ther. 2016 Dec; 3(2):323-336. PMID: 27747581.
      View in: PubMed
    46. Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. J Blood Med. 2016; 7:129-37. PMID: 27445511.
      View in: PubMed
    47. Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guérin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97. PMID: 27216253.
      View in: PubMed
    48. Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J. Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. Antimicrob Agents Chemother. 2016 06; 60(6):3398-406. PMID: 27001815.
      View in: PubMed
    49. Maziarz RT, Guérin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L. Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant. Int J Hematol Oncol. 2016 Sep; 5(2):63-75. PMID: 30302205.
      View in: PubMed
    50. Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Res Treat. 2016 05; 157(1):145-56. PMID: 27107569.
      View in: PubMed
    51. Guérin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother. 2016 Jun; 17(9):1189-96. PMID: 27052735.
      View in: PubMed
    52. Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. Clin Ther. 2016 05; 38(5):1205-16. PMID: 27045991.
      View in: PubMed
    53. Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B. Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. Springerplus. 2016; 5:395. PMID: 27047721.
      View in: PubMed
    54. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites. Clin Ther. 2016 04; 38(4):905-17. PMID: 26947172.
      View in: PubMed
    55. Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guérin A. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Curr Med Res Opin. 2016; 32(2):385-94. PMID: 26651842.
      View in: PubMed
    56. Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guérin A. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. J Med Econ. 2016; 19(4):414-23. PMID: 27032967.
      View in: PubMed
    57. Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Dec 29; 15:167. PMID: 26714746.
      View in: PubMed
    58. Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey. Cancer Med. 2016 Feb; 5(2):209-20. PMID: 26686532.
      View in: PubMed
    59. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol. 2015; 4:31. PMID: 26693096.
      View in: PubMed
    60. Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respir Med. 2015 Dec; 109(12):1582-8. PMID: 26607877.
      View in: PubMed
    61. Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ. Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer. Breast Cancer (Auckl). 2015; 9:67-72. PMID: 26380551.
      View in: PubMed
    62. Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. Expert Opin Pharmacother. 2015; 16(14):2101-11. PMID: 26290278.
      View in: PubMed
    63. Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin. 2015 Aug; 31(8):1573-82. PMID: 26074049.
      View in: PubMed
    64. Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer. J Comp Eff Res. 2015 Aug; 4(4):315-26. PMID: 26274793.
      View in: PubMed
    65. Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA. Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther. 2015 Sep; 6(3):339-55. PMID: 26202185.
      View in: PubMed
    66. Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clin Ther. 2015 Aug; 37(8):1713-25.e3. PMID: 26111918.
      View in: PubMed
    67. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. Int J Breast Cancer. 2015; 2015:240750. PMID: 26078883.
      View in: PubMed
    68. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin. 2015 Jun; 31(6):1095-103. PMID: 25971725.
      View in: PubMed
    69. Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiol. 2015 Jun; 39(3):307-12. PMID: 25914136.
      View in: PubMed
    70. Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ. Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. J Manag Care Spec Pharm. 2015 Apr; 21(4):308-18. PMID: 25803764.
      View in: PubMed
    71. Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health. 2015 Mar; 18(2):198-205. PMID: 25773555.
      View in: PubMed
    72. Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Curr Med Res Opin. 2015 Mar; 31(3):537-45. PMID: 25598441.
      View in: PubMed
    73. Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy. J Med Econ. 2015 Mar; 18(3):241-8. PMID: 25422992.
      View in: PubMed
    74. Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. Fertil Steril. 2015 Jan; 103(1):163-71. PMID: 25455535.
      View in: PubMed
    75. Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin. 2015 Feb; 31(2):263-73. PMID: 25350226.
      View in: PubMed
    76. Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin. 2015 Feb; 31(2):315-22. PMID: 25356603.
      View in: PubMed
    77. Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. Lung Cancer. 2014 Dec; 86(3):350-7. PMID: 25439437.
      View in: PubMed
    78. Mody R, Guérin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Prevalence and risk of developing comorbid conditions in patients with chronic constipation. Curr Med Res Opin. 2014 Dec; 30(12):2505-13. PMID: 25215427.
      View in: PubMed
    79. Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin. 2014 Jul; 30(7):1345-52. PMID: 24640967.
      View in: PubMed
    80. Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China. Pharmacoeconomics. 2014 Mar; 32(3):305-13. PMID: 24500859.
      View in: PubMed
    81. Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. Appl Health Econ Health Policy. 2014 Feb; 12(1):85-93. PMID: 24385260.
      View in: PubMed
    82. DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):245-51. PMID: 24393622.
      View in: PubMed
    83. Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ. 2014 Feb; 17(2):89-98. PMID: 24188054.
      View in: PubMed
    84. Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev. 2014 Mar; 40(2):285-92. PMID: 24112812.
      View in: PubMed
    85. Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L. Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Oncol Pract. 2013 Sep; 9(5):e212-9. PMID: 23943889.
      View in: PubMed
    86. Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2013; 16(2):260-2. PMID: 23176287.
      View in: PubMed
    87. Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ. 2013; 16(2):278-88. PMID: 23153318.
      View in: PubMed
    88. Wu EQ, Forsythe A, Guérin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012 Nov; 19(6):e157-66. PMID: 21317625.
      View in: PubMed
    89. Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. Hosp Pract (1995). 2012 Oct; 40(4):40-8. PMID: 23299035.
      View in: PubMed
    90. Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012 Sep-Oct; 15(6):940-7. PMID: 22999145.
      View in: PubMed
    91. Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012 Jul; 29(7):620-34. PMID: 22843208.
      View in: PubMed
    92. Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs. 2012 Jul 01; 26(7):581-600. PMID: 22712698.
      View in: PubMed
    93. Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ. 2012; 15(6):1078-87. PMID: 22537226.
      View in: PubMed
    94. Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Med Econ. 2013; 16(1):125-33. PMID: 22587385.
      View in: PubMed
    95. Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:130-7. PMID: 22552988.
      View in: PubMed
    96. Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. J Med Econ. 2012; 15(4):786-95. PMID: 22475042.
      View in: PubMed
    97. Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin. 2012 Apr; 28(4):591-9. PMID: 22352883.
      View in: PubMed
    98. Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population. Manag Care. 2012 Jan; 21(1):49-58. PMID: 22332457.
      View in: PubMed
    99. Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012 Jan; 124(1):124-32. PMID: 22314122.
      View in: PubMed
    100. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011 Dec; 105(12):1861-71. PMID: 21807487.
      View in: PubMed
    101. Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ. 2011; 14(5):542-52. PMID: 21728912.
      View in: PubMed
    102. Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH. Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs. J Med Econ. 2011; 14(4):508-15. PMID: 21692605.
      View in: PubMed
    103. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011; 14(4):486-96. PMID: 21679019.
      View in: PubMed
    104. Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):326-35. PMID: 21700528.
      View in: PubMed
    105. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011; 14(3):315-23. PMID: 21500975.
      View in: PubMed
    106. Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP. Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ. 2011; 14(3):267-78. PMID: 21446895.
      View in: PubMed
    107. Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr Med Res Opin. 2011 Jun; 27(6):1089-96. PMID: 21438794.
      View in: PubMed
    108. Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother. 2011 Apr; 45(4):441-51. PMID: 21415162.
      View in: PubMed
    109. Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. Am Health Drug Benefits. 2011 Mar; 4(2):78-87. PMID: 25126340.
      View in: PubMed
    110. Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011 Feb 01; 12(1):51-62. PMID: 21110526.
      View in: PubMed
    111. Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. Am J Cardiovasc Drugs. 2011; 11(1):21-32. PMID: 21142294.
      View in: PubMed
    112. Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig. 2011; 31(9):665-74. PMID: 21819162.
      View in: PubMed
    113. Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M. Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. J Med Econ. 2010; 13(4):599-609. PMID: 20879834.
      View in: PubMed
    114. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010 Sep; 26(9):2065-76. PMID: 20629600.
      View in: PubMed
    115. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010 Jan; 26(1):61-9. PMID: 19905880.
      View in: PubMed
    116. Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. J Med Econ. 2010; 13(2):314-23. PMID: 20504111.
      View in: PubMed
    117. Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2009 Nov; 21(11):1302-9. PMID: 19465858.
      View in: PubMed
    118. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009 Oct; 25(10):2429-38. PMID: 19663687.
      View in: PubMed
    119. Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ. 2009 Jun; 12(2):124-35. PMID: 19566483.
      View in: PubMed
    120. Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009 May; 36(5):1032-40. PMID: 19369467.
      View in: PubMed
    121. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. PMID: 19352339.
      View in: PubMed
    122. Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R. Antidepressant treatment patterns and costs among US employees. J Med Econ. 2009 Mar; 12(1):36-45. PMID: 19450063.
      View in: PubMed
    123. Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008 Dec; 24(12):3493-501. PMID: 19032131.
      View in: PubMed
    124. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41. PMID: 18853973.
      View in: PubMed
    125. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. PMID: 18848553.
      View in: PubMed
    126. Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation. 2008 Jul 29; 118(5):491-7. PMID: 18625894.
      View in: PubMed
    127. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health. 2007 Nov-Dec; 10(6):443-50. PMID: 17970926.
      View in: PubMed
    128. Wu EQ, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health. 2007 Sep-Oct; 10(5):408-14. PMID: 17888106.
      View in: PubMed
    129. Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin. 2007 Sep; 23(9):2157-69. PMID: 17669232.
      View in: PubMed
    130. Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm. 2007 Sep; 13(7):561-9. PMID: 17874862.
      View in: PubMed
    131. Colice G, Wu EQ, Birnbaum H, Daher M, Maryna M. Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma. 2007 Jul-Aug; 44(6):479-83. PMID: 17654136.
      View in: PubMed
    132. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring). 2007 Feb; 15(2):511-21. PMID: 17299125.
      View in: PubMed
    133. Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006 Oct; 37(10):2567-72. PMID: 16946158.
      View in: PubMed
    134. Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006 Nov; 36(11):1535-40. PMID: 16907994.
      View in: PubMed
    135. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006 Aug; 48(8):794-802. PMID: 16902372.
      View in: PubMed
    136. Wu EQ, Birnbaum H, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ. A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis. Curr Med Res Opin. 2006 Mar; 22(3):495-500. PMID: 16574033.
      View in: PubMed
    137. Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H. Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population. Pharmacoeconomics. 2006; 24(1):55-65. PMID: 16445303.
      View in: PubMed
    138. Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005 Oct; 21(10):1693-9. PMID: 16238910.
      View in: PubMed
    139. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005 Sep; 66(9):1122-9. PMID: 16187769.
      View in: PubMed
    140. Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005 Oct 15; 58(8):668-76. PMID: 16023620.
      View in: PubMed
    141. Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005 May; 47(5):439-46. PMID: 15891521.
      View in: PubMed
    Wu's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (463) concept(s)
    _
    Co-Authors Expand Description
    See all (2) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)